BACKGROUND: Ki-67 is increasingly being used as a response biomarker in window of opportunity, pre-surgical trials for breast cancer patients. Since Ki-67 is often higher at surgery than at baseline core biopsy in subjects allocated to placebo, we investigated which factors affected this change. PATIENTS AND METHODS: We retrieved data from 274 patients who received no active treatment in three consecutive pre-surgical trials from a single institution. We assessed the association between changes in Ki-67 from diagnostic biopsy to surgical specimen and the following factors: age, body mass index, tumor prognostic and predictive factors, including immunohistochemical molecular subtype, number and size of biopsy specimens, time from biopsy to surgery, circulating insulin-like growth factor-I, sex hormone-binding globulin and hsCRP. RESULTS: A total of 269 patients with paired measures of Ki-67 at biopsy and surgery were analyzed. Overall, the mean (±SD) change was 2.2 ± 9.2% after a median interval of 41 days (inter-quartile range 33-48). Molecular subtype was the only factor associated with a significant change of Ki-67 (P = 0.004), with a mean absolute increase of 5.3% [95% confidence interval (CI): 2.3-8.3, P = 0.0005] in estrogen receptor-negative HER2-positive tumors (n = 36) and 5.4% (95% CI: 2.9-7.9, P < 0.0001) in triple-negative tumors (n = 78). No significant change in luminal-A (n = 46), luminal-B (n = 85) and luminal-B HER2-positive (n = 24) tumors was observed. CONCLUSIONS: A significant increase in Ki-67 from baseline biopsy to end point surgery in untreated subjects was ascertained in HER2-positive and triple-negative tumors. This biological association suggests a real increase in cancer proliferation, possibly as a result of a biopsy-driven wound healing effect, and should be considered in the design and interpretation of pre-surgical studies.
Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials / S. Gandini, A. Guerrieri-Gonzaga, G. Pruneri, D. Serrano, M. Cazzaniga, M. Lazzeroni, P. Veronesi, H. Johansson, B. Bonanni, G. Viale, A. Decensi. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 25:3(2014 Mar), pp. mdt528.618-mdt528.623.
|Titolo:||Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials|
|Parole Chiave:||Ki 67 antigen; Molecular subtype breast cancer; Neoadjuvant treatment breast cancer; Triple-negative breast cancer; Window of opportunity|
|Settore Scientifico Disciplinare:||Settore MED/08 - Anatomia Patologica|
Settore MED/18 - Chirurgia Generale
|Data di pubblicazione:||mar-2014|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1093/annonc/mdt528|
|Appare nelle tipologie:||01 - Articolo su periodico|